Physician profile
John P Forney
NPI 1437314895
$4,108.09
in general payments reported to CMS, 2019-2025
28 companies · $894 in 2025
The $894 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $308 · 2020: $55.29 · 2021: $51.80 · 2022: $478 · 2023: $1,174 · 2024: $1,147 · 2025: $894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,170 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,169.80 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,744.01 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Lilly USA, LLC | $480.94 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $370.55 | 2022-2025 | |
| Novo Nordisk INC | $283.82 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $182.15 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $150.51 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $127.63 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.61 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Xeris Pharmaceuticals, INC. | $76.35 | 2023-2025 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $74.09 | 2022-2025 | Trelegy Ellipta, Bexsero, Arexvy |
| Amgen INC. | $53.88 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $49.48 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $43.84 | 2024-2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $40.34 | 2023-2025 | Rexulti |
| Sanofi Pasteur INC. | $39.13 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $33.94 | 2025 | Dexcom G6 Transmitter |
| Cequr Corporation | $32.47 | 2024-2025 | Cequr Simplicity |
| Biohaven Pharmaceuticals, INC. | $30.93 | 2021 | |
| Amarin Pharma, INC. | $27.08 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $22.89 | 2024 | Austedo Xr |
| Merck Sharp & Dohme LLC | $20.87 | 2021 | |
| Circassia INC. | $19.87 | 2019 | |
| Exact Sciences Corporation | $17.59 | 2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $16.90 | 2022 | |
| Aimmune Therapeutics, INC. | $15.62 | 2025 | Zenpep |
| Daiichi Sankyo INC. | $14.36 | 2019 | |
| Neurocrine Biosciences, INC. | $14.24 | 2023 | Ingrezza |
| Sanofi-Aventis U.S. LLC | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Forney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.